Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Ottawa

$156,060.00

A-CD estrogens as alternatives to Estrogen-based hormone replacement therapy

EF 2011-12

Résumé
In previous work we have synthesized new molecules that can mediate effects on two types of proteins (estrogen receptors),called ERalpha and ER beta, that receive estrogenic signals. The ERalpha can promote breast cancer growth but it is also the receptor in the brain that controls temperature control (hot flashes). In contrast the ERbeta antagonizes the cancer promoting effects of the ERalpha. This proposal will test the safety and efficacy of novel drugs that preferentially activate with the ERbeta receptor to both inhibit the breast cancer-associated effects of estrogen while retaining sufficient ERalpha activity to prevent hot flashes.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
256955
Name
Pratt Christine M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Clinical
Prcname2
Proof of Principle
Projecttitle
A-CD estrogens as alternatives to Estrogen-based hormone replacement therapy
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$156,060
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Estrogen; Menopause; Rat Model; Safety Studies
Abstract
In previous work we have synthesized new molecules that can mediate effects on two types of proteins (estrogen receptors),called ERalpha and ER beta, that receive estrogenic signals. The ERalpha can promote breast cancer growth but it is also the receptor in the brain that controls temperature control (hot flashes). In contrast the ERbeta antagonizes the cancer promoting effects of the ERalpha. This proposal will test the safety and efficacy of novel drugs that preferentially activate with the ERbeta receptor to both inhibit the breast cancer-associated effects of estrogen while retaining sufficient ERalpha activity to prevent hot flashes.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pratt, Christine M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $156,060~ $0~